AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Aardvark Therapeutics, Inc. Common Stock
Video analysis: AARD
All videosNo video analysis for this stock yet. Request one from our team.
News: AARD
AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
A securities class action alleges Aardvark Therapeutics' Chief Executive Officer, Chief Financial Officer, and former Chief Operating Officer controlled the safety representations about ARD-101 that preceded a Phase 3 pause and a full FDA clinical hold A securities class action alleges Aardvark Therapeutics' Chief Executive Officer, Chief Financial Officer, and former Chief Operating Officer controlled the safety representations about ARD-101 that preceded a Phase 3 pause and a full FDA clinical hold
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
AARDVARK THERAPEUTICS, INC. INVESTORS WITH LOSSES HAVE UNTIL OCTOBER 13, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD) of the October 13, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline
SAN FRANCISCO, Sept. 15, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc. IF YOU SUFFERED A LOSS ON YOUR AARDVARK THERAPEUTICS, INC.
AARD DEADLINE: Levi & Korsinsky Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
Aardvark Therapeutics' shares lost more than 70% of their IPO value across two market events after the Company disclosed a Phase 3 safety pause and then a full FDA clinical hold on ARD-101, which a securities class action alleges corrected earlier representations that the drug was "99% gut-restricted" with minimal systemic exposure Aardvark Therapeutics' shares lost more than 70% of their IPO value across two market events after the Company disclosed a Phase 3 safety pause and then a full FDA clinical hold on ARD-101, which a securities class action alleges corrected earlier representations that the drug was "99% gut-restricted" with minimal systemic exposure
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline
SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a national shareholder rights firm, notifies investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) of a pending securities class action lawsuit.
AARD EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aardvark To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in (a) Aardvark common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 13, 2025 (the "IPO" or "Offering"); and/or (b) Aardvark securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 14, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aardvark Therapeutics, Inc. ("Aardvark" or the "Company") (NASDAQ: AARD) and reminds investors of the October 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
